...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith AGM

"the initial focus of Cencora’s work will be in evaluating regulatory and market access to provide insights into potential barriers and opportunities for ZEN-3694's introduction"

wonder what Donald will say when Cencora tells him that he is the largest "potential barrier" in moving this science & company forward??

Share
New Message
Please login to post a reply